Novartis France Novartis in the world Divisions contact Home Novartis in France Innovation Corporate citizenship Products Media Career Baclofen Temporary Use Recommendation (RTU) From March 17, following a decision by the National Medicines Safety Agency (ANSM), doctors can prescribe baclofen in patients requiring treatment for alcohol dependence, according to a very supervised protocol of implementation and monitoring of this prescription, developed by the ANSM, within the framework of a Temporary Recommendation for Use (RTU). You will find all the necessary information on the ANSM website Transparency of relations From April 1, 2014, Access the single site Regarding previous publications, you can consult them at these addresses: Access Novartis Pharma publications Access Sandoz publications Access Alcon's publications Access Novartis Consumer Healthcare publications Access the publications of Novartis Vaccines & Diagnostics News 07/17/2014 Novartis maintained the accelerated pace of innovation in the second quarter, thus reconfirming the outlook for the full year 2% increase in net sales in the second quarter (Q2), with core operating leverage in Q2 and the first half (S1) (...) Milestones in innovation in Q2, strengthening pipeline strength and growth prospects (...) Very effective marketing, in Q2, of growth products and in emerging countries by all divisions (...) Q2 core margin improvement (cc), mainly due to projects aimed at increasing productivity (...) Group outlook reconfirmed for 2014: increase in Group net sales at a single-digit rate between the low and mid-range (cc); core operating profit growing faster than sales (at a rate now refined to single digits between the middle and top of the cc range) (...) Download the Group's press release (370 KB) 04/24/2014 Novartis: strong sales and profit growth in the first quarter of 2014; strong innovation strengthens growth prospects as the company transforms its portfolio Net sales of USD 14.0 billion, up 1% (+ 3% cc) with all divisions contributing to growth; core operating leverage (tcc) supported by Pharmaceuticals and a decrease in Corporate costs (...) Progress of innovation, with major clearances, recommendations and positive results Xolair authorized by the EU and the United States for chronic spontaneous / idiopathic urticaria (UCS / UCI) Phase III trial of LCZ696 in acute heart failure terminated prematurely with very positive interim results Bexser recommended for inclusion in the UK's National Immunization Program and designated “breakthrough treatment” by the FDA in the US Acquisition of CoStim Pharmaceuticals to accelerate the cancer immunotherapy program and strengthen combination treatments (...) Download the Group's press release (370 KB) Investors SWX NYSE Stock performance Websites in the world: Website of other divisions in France: Novartis in the world Find a Novartis site Follow us All Novartis news around the world Subscribe to our RSS feed © 2014 Novartis France Terms of Use Data Protection Policy Sitemap This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and / or do not wish to have cookies placed when using the site, visit About cookies page. Don't show me this again